ID   MMEL1_RAT               Reviewed;         774 AA.
AC   P0C1T0;
DT   05-SEP-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-SEP-2006, sequence version 1.
DT   29-MAY-2024, entry version 103.
DE   RecName: Full=Membrane metallo-endopeptidase-like 1;
DE            EC=3.4.24.11;
DE   AltName: Full=NEP2(m);
DE   AltName: Full=Neprilysin II;
DE            Short=NEPII;
DE   AltName: Full=Neprilysin-2;
DE            Short=NEP2;
DE            Short=NL2;
DE   Contains:
DE     RecName: Full=Membrane metallo-endopeptidase-like 1, soluble form;
DE     AltName: Full=Neprilysin-2 secreted;
DE              Short=NEP2(s);
GN   Name=Mmel1; Synonyms=Mell1, Nep2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), AND TISSUE SPECIFICITY.
RX   PubMed=10814502; DOI=10.1006/bbrc.2000.2664;
RA   Ouimet T., Facchinetti P., Rose C., Bonhomme M.-C., Gros C.,
RA   Schwartz J.-C.;
RT   "Neprilysin II: a putative novel metalloprotease and its isoforms in CNS
RT   and testis.";
RL   Biochem. Biophys. Res. Commun. 271:565-570(2000).
RN   [2]
RP   ERRATUM OF PUBMED:10814502.
RA   Ouimet T., Facchinetti P., Rose C., Bonhomme M.-C., Gros C.,
RA   Schwartz J.-C.;
RL   Biochem. Biophys. Res. Commun. 275:247-247(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [4]
RP   TISSUE SPECIFICITY.
RX   PubMed=12710972; DOI=10.1016/s0306-4522(02)01002-3;
RA   Facchinetti P., Rose C., Schwartz J.C., Ouimet T.;
RT   "Ontogeny, regional and cellular distribution of the novel metalloprotease
RT   neprilysin 2 in the rat: a comparison with neprilysin and endothelin-
RT   converting enzyme-1.";
RL   Neuroscience 118:627-639(2003).
RN   [5]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ARG-131; SER-133; ASN-567
RP   AND LEU-739.
RX   PubMed=15294904; DOI=10.1074/jbc.m407333200;
RA   Voisin S., Rognan D., Gros C., Ouimet T.;
RT   "A three-dimensional model of the neprilysin 2 active site based on the X-
RT   ray structure of neprilysin. Identification of residues involved in
RT   substrate hydrolysis and inhibitor binding of neprilysin 2.";
RL   J. Biol. Chem. 279:46172-46181(2004).
RN   [6]
RP   GLYCOSYLATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11964170; DOI=10.1042/0264-6021:3630697;
RA   Rose C., Voisin S., Gros C., Schwartz J.-C., Ouimet T.;
RT   "Cell-specific activity of neprilysin 2 isoforms and enzymic specificity
RT   compared with neprilysin.";
RL   Biochem. J. 363:697-705(2002).
RN   [7]
RP   MUTAGENESIS OF PRO-751; PRO-764 AND TRP-774.
RX   PubMed=16081046; DOI=10.1016/j.bbrc.2005.07.081;
RA   Voisin S., Ouimet T.;
RT   "The ultimate tryptophan residue of neprilysin 2 is not involved in protein
RT   maturation and enzymatic activity.";
RL   Biochem. Biophys. Res. Commun. 335:356-360(2005).
CC   -!- FUNCTION: Metalloprotease involved in sperm function, possibly by
CC       modulating the processes of fertilization and early embryonic
CC       development. Degrades a broad variety of small peptides with a
CC       preference for peptides shorter than 3 kDa containing neutral bulky
CC       aliphatic or aromatic amino acid residues. Shares the same substrate
CC       specificity with MME and cleaves peptides at the same amide bond (By
CC       similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Preferential cleavage of polypeptides between hydrophobic
CC         residues, particularly with Phe or Tyr at P1'.; EC=3.4.24.11;
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- ACTIVITY REGULATION: Inhibited by thiorphan and phosphoramidon.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=62 uM for Tyrosyl-D-Ala(2)-Leu(5)-enkephalin
CC         {ECO:0000269|PubMed:11964170, ECO:0000269|PubMed:15294904};
CC         KM=27 uM for Suc-AA-F-AMC (Membrane metallo-endopeptidase-like 1)
CC         {ECO:0000269|PubMed:11964170, ECO:0000269|PubMed:15294904};
CC         KM=50 uM for Suc-AA-F-AMC (Membrane metallo-endopeptidase-like 1,
CC         soluble form) {ECO:0000269|PubMed:11964170,
CC         ECO:0000269|PubMed:15294904};
CC         KM=40 uM for Suc-AA-V-AMC (Membrane metallo-endopeptidase-like 1)
CC         {ECO:0000269|PubMed:11964170, ECO:0000269|PubMed:15294904};
CC         KM=100 uM for Suc-AA-V-AMC (Membrane metallo-endopeptidase-like 1,
CC         soluble form) {ECO:0000269|PubMed:11964170,
CC         ECO:0000269|PubMed:15294904};
CC         KM=23 uM for Suc-G-LF-AMC (Membrane metallo-endopeptidase-like 1)
CC         {ECO:0000269|PubMed:11964170, ECO:0000269|PubMed:15294904};
CC         KM=35 uM for Suc-G-LF-AMC (Membrane metallo-endopeptidase-like 1,
CC         soluble form) {ECO:0000269|PubMed:11964170,
CC         ECO:0000269|PubMed:15294904};
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type II membrane protein.
CC       Secreted. Note=A secreted form produced by proteolytic cleavage also
CC       exists. {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P0C1T0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P0C1T0-2; Sequence=VSP_020292;
CC       Name=3;
CC         IsoId=P0C1T0-3; Sequence=VSP_020293;
CC       Name=4;
CC         IsoId=P0C1T0-4; Sequence=VSP_020294;
CC   -!- TISSUE SPECIFICITY: Specifically expressed in testis and central
CC       nervous system (CNS) (at protein level). Restricted to developing and
CC       differentiating fields of the CNS. The soluble form is expressed in
CC       round spermatides. {ECO:0000269|PubMed:10814502,
CC       ECO:0000269|PubMed:12710972}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:11964170}.
CC   -!- SIMILARITY: Belongs to the peptidase M13 family. {ECO:0000255|PROSITE-
CC       ProRule:PRU01233, ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AABR03040205; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   AlphaFoldDB; P0C1T0; -.
DR   SMR; P0C1T0; -.
DR   STRING; 10116.ENSRNOP00000017957; -.
DR   MEROPS; M13.008; -.
DR   GlyCosmos; P0C1T0; 8 sites, No reported glycans.
DR   GlyGen; P0C1T0; 8 sites.
DR   PhosphoSitePlus; P0C1T0; -.
DR   PaxDb; 10116-ENSRNOP00000017957; -.
DR   AGR; RGD:1309299; -.
DR   RGD; 1309299; Mmel1.
DR   VEuPathDB; HostDB:ENSRNOG00000012593; -.
DR   eggNOG; KOG3624; Eukaryota.
DR   HOGENOM; CLU_006187_4_1_1; -.
DR   InParanoid; P0C1T0; -.
DR   BRENDA; 3.4.24.B14; 5301.
DR   PRO; PR:P0C1T0; -.
DR   Proteomes; UP000002494; Chromosome 5.
DR   Bgee; ENSRNOG00000012593; Expressed in testis and 5 other cell types or tissues.
DR   ExpressionAtlas; P0C1T0; baseline and differential.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0005794; C:Golgi apparatus; ISO:RGD.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0004175; F:endopeptidase activity; ISO:RGD.
DR   GO; GO:0004222; F:metalloendopeptidase activity; IDA:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IDA:RGD.
DR   GO; GO:0016485; P:protein processing; IBA:GO_Central.
DR   GO; GO:0006508; P:proteolysis; ISO:RGD.
DR   CDD; cd08662; M13; 1.
DR   Gene3D; 3.40.390.10; Collagenase (Catalytic Domain); 1.
DR   Gene3D; 1.10.1380.10; Neutral endopeptidase , domain2; 1.
DR   InterPro; IPR024079; MetalloPept_cat_dom_sf.
DR   InterPro; IPR000718; Peptidase_M13.
DR   InterPro; IPR018497; Peptidase_M13_C.
DR   InterPro; IPR042089; Peptidase_M13_dom_2.
DR   InterPro; IPR008753; Peptidase_M13_N.
DR   PANTHER; PTHR11733:SF141; MEMBRANE METALLO-ENDOPEPTIDASE-LIKE 1; 1.
DR   PANTHER; PTHR11733; ZINC METALLOPROTEASE FAMILY M13 NEPRILYSIN-RELATED; 1.
DR   Pfam; PF01431; Peptidase_M13; 1.
DR   Pfam; PF05649; Peptidase_M13_N; 1.
DR   PRINTS; PR00786; NEPRILYSIN.
DR   SUPFAM; SSF55486; Metalloproteases ('zincins'), catalytic domain; 1.
DR   PROSITE; PS51885; NEPRILYSIN; 1.
DR   PROSITE; PS00142; ZINC_PROTEASE; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Coiled coil; Disulfide bond; Glycoprotein; Hydrolase;
KW   Membrane; Metal-binding; Metalloprotease; Protease; Reference proteome;
KW   Secreted; Signal-anchor; Transmembrane; Transmembrane helix; Zinc.
FT   CHAIN           1..774
FT                   /note="Membrane metallo-endopeptidase-like 1"
FT                   /id="PRO_0000248419"
FT   CHAIN           73..774
FT                   /note="Membrane metallo-endopeptidase-like 1, soluble form"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000248420"
FT   TOPO_DOM        1..26
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        27..47
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        48..774
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          84..774
FT                   /note="Peptidase M13"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   COILED          532..558
FT                   /evidence="ECO:0000255"
FT   MOTIF           14..21
FT                   /note="Stop-transfer sequence"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        609
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233,
FT                   ECO:0000255|PROSITE-ProRule:PRU10095"
FT   ACT_SITE        675
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   BINDING         131
FT                   /ligand="a peptide"
FT                   /ligand_id="ChEBI:CHEBI:60466"
FT                   /ligand_note="substrate"
FT                   /evidence="ECO:0000305"
FT   BINDING         608
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233,
FT                   ECO:0000255|PROSITE-ProRule:PRU10095"
FT   BINDING         612
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233,
FT                   ECO:0000255|PROSITE-ProRule:PRU10095"
FT   BINDING         671
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   SITE            72..73
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        173
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        203
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        239
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        312
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        345
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        633
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        652
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        703
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        85..90
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   DISULFID        108..759
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   DISULFID        116..719
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   DISULFID        171..434
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   DISULFID        645..771
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01233"
FT   VAR_SEQ         51..73
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10814502"
FT                   /id="VSP_020292"
FT   VAR_SEQ         246..267
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10814502"
FT                   /id="VSP_020293"
FT   VAR_SEQ         303..313
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_020294"
FT   MUTAGEN         131
FT                   /note="R->M: Impairs binding of free carboxylate group of
FT                   substrates."
FT                   /evidence="ECO:0000269|PubMed:15294904"
FT   MUTAGEN         133
FT                   /note="S->G: Impairs both substrate-binding and enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:15294904"
FT   MUTAGEN         567
FT                   /note="N->G: Impairs the enzyme specificity."
FT                   /evidence="ECO:0000269|PubMed:15294904"
FT   MUTAGEN         739
FT                   /note="L->G: Impairs both substrate-binding and enzyme
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:15294904"
FT   MUTAGEN         751
FT                   /note="P->A: Loss of function."
FT                   /evidence="ECO:0000269|PubMed:16081046"
FT   MUTAGEN         764
FT                   /note="P->Y: Induces a 3-fold decrease of specific
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:16081046"
FT   MUTAGEN         774
FT                   /note="W->F: No effect."
FT                   /evidence="ECO:0000269|PubMed:16081046"
SQ   SEQUENCE   774 AA;  89197 MW;  F95E2088CA4B64AD CRC64;
     MGKSESSVGM MERADNCGRR RLGFVECGLL VLLTLLLMGA IVTLGVFYSI GKQLPLLNSL
     LHVSRHERTV VKRVLRDSSQ KSDICTTPSC VIAAARILQN MDQSKKPCDN FYQYACGGWL
     RHHVIPETNS RYSVFDILRD ELEVILKGVL EDSSVQHRPA VEKAKTLYRS CMNQSVIEKR
     DSEPLLNVLD MIGGWPVAMD KWNETMGPKW ELERQLAVLN SQFNRRVLID LFIWNDDQNS
     SRHVIYIDQP TLGMPSREYY FKEDSHRVRE AYLQFMTSVA TMLRRDLNLP GETDLVQEEM
     AQVLHLETHL ANATVPQEKR HDVTALYHRM GLEELQERFG LKGFNWTLFI QNVLSSVQVE
     LLPNEEVVVY GIPYLENLEE IIDVFPAQTL QNYLVWRLVL DRIGSLSQRF KEARVDYRKA
     LYGTTMEEVR WRECVSYVNS NMESAVGSLY IKRAFSKDSK SIVSELIEKI RSVFVDNLDE
     LNWMDEESKK KAQEKALNIR EQIGYPDYIL EDNNRHLDEE YSSLTFSEDL YFENGLQNLK
     NNAQRSLKKL REKVDQNLWI IGAAVVNAFY SPNRNLIVFP AGILQPPFFS KDQPQALNFG
     GIGMVIGHEI THGFDDNGRN FDKNGNMLDW WSNFSARHFR QQSQCMIYQY SNFSWELADN
     QNVNGFSTLG ENIADNGGVR QAYKAYLQWL AEGGRDQRLP GLNLTYAQLF FINYAQVWCG
     SYRPEFAIQS IKTDVHSPLN AQVLGSLQNL PGFSEAFHCP RGSPMHPMNR CRIW
//
